This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): EBVnRNA, nanoRNA cancer therapy
The nRNA technology platform is essentially antisense siRNA gene silencing. The company's proprietary chemistry allows the production of a chirally pure RNA that is proposed to result in more efficient targeting/silencing with less toxicity.The nRNAs are also proposed to be more stable and allow for more routes of administration.
The direct gene target for EBV-nRNA has not been specified, but we assume it to target a gene of the Epstein-Barr Virus.
Additional information available to subscribers only: